Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Colorcon
Julphar
Dow
Harvard Business School
McKinsey
UBS
Mallinckrodt
Fish and Richardson

Generated: November 19, 2018

DrugPatentWatch Database Preview

BASAGLAR Drug Profile

« Back to Dashboard

When do Basaglar patents expire, and when can generic versions of Basaglar launch?

Basaglar is a drug marketed by Eli Lilly And Co and is included in one NDA.

The generic ingredient in BASAGLAR is insulin glargine. There are forty drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the insulin glargine profile page.

Drug patent expirations by year for BASAGLAR
Generic Entry Opportunity Date for BASAGLAR
Generic Entry Date for BASAGLAR*:
Constraining patent/regulatory exclusivity:
NEW PRODUCT
NDA:
Dosage:
SOLUTION;SUBCUTANEOUS

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Pharmacology for BASAGLAR
Ingredient-typeInsulin
Drug ClassInsulin Analog
Medical Subject Heading (MeSH) Categories for BASAGLAR

US Patents and Regulatory Information for BASAGLAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co BASAGLAR insulin glargine SOLUTION;SUBCUTANEOUS 205692-001 Dec 16, 2015 RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set.
Subscribe to access the full database, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Colorcon
Julphar
Dow
Harvard Business School
McKinsey
UBS
Mallinckrodt
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.